|
π
|
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
16 auth.
G. Attard,
A. Reid,
T. Yap,
F. Raynaud,
M. Dowsett,
S. Settatree,
M. Barrett,
C. Parker,
V. Martins,
E. Folkerd,
...
Jeremy Clark,
C. Cooper,
S. Kaye,
D. Dearnaley,
Gloria Lee,
J. D. de Bono
|
9 |
2008 |
9
π
|
|
π
|
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
34 auth.
A. Folkes,
K. Ahmadi,
W. Alderton,
Sonia Alix,
S. Baker,
G. Box,
Irina S. Chuckowree,
P. Clarke,
P. Depledge,
S. Eccles,
L. Friedman,
A. Hayes,
T. Hancox,
A. Kugendradas,
Letitia Lensun,
...
P. Moore,
A. Olivero,
Jodie Pang,
Sonal Patel,
Giles Pergl-Wilson,
F. Raynaud,
Anthony Robson,
N. Saghir,
L. Salphati,
S. Sohal,
M. Ultsch,
M. Valenti,
H. Wallweber,
N. Wan,
C. Wiesmann,
P. Workman,
A. Zhyvoloup,
M. Zvelebil,
S. Shuttleworth
|
9 |
2008 |
9
π
|
|
π¬
|
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
T. Yap,
M. Garrett,
M. Walton,
F. Raynaud,
J. D. de Bono,
P. Workman
|
9 |
2008 |
9
π¬
|
|
π
|
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
15 auth.
U. Banerji,
A. OβDonnell,
M. Scurr,
S. Pacey,
S. Stapleton,
Yasmin Asad,
Laura Simmons,
Alison Maloney,
F. Raynaud,
Maeli J Campbell,
...
M. Walton,
S. Lakhani,
S. Kaye,
P. Workman,
I. Judson
|
8 |
2005 |
8
π
|
|
π
|
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
37 auth.
S. Eccles,
A. Massey,
F. Raynaud,
S. Sharp,
G. Box,
M. Valenti,
Lisa Patterson,
A. K. de Haven Brandon,
S. Gowan,
F. Boxall,
W. Aherne,
M. Rowlands,
A. Hayes,
V. Martins,
Frederique Urban,
...
K. Boxall,
C. Prodromou,
L. Pearl,
K. James,
Thomas P Matthews,
K. Cheung,
A. Kalusa,
K. Jones,
E. McDonald,
X. Barril,
P. Brough,
J. Cansfield,
B. Dymock,
M. Drysdale,
H. Finch,
R. Howes,
R. Hubbard,
A. Surgenor,
P. Webb,
Mike Wood,
L. Wright,
P. Workman
|
8 |
2008 |
8
π
|
|
π
|
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
7 auth.
J. Waters,
A. Webb,
D. Cunningham,
P. Clarke,
F. Raynaud,
F. Stefano,
...
F. Cotter
|
8 |
2000 |
8
π
|
|
π
|
Effect of sleep deprivation on the human metabolome
13 auth.
Sarah K. Davies,
J. Ang,
V. Revell,
B. Holmes,
A. Mann,
F. Robertson,
N. Cui,
B. Middleton,
K. Ackermann,
M. Kayser,
...
A. Thumser,
F. Raynaud,
D. Skene
|
8 |
2014 |
8
π
|
|
π
|
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
37 auth.
P. Brough,
W. Aherne,
X. Barril,
Jenifer Borgognoni,
K. Boxall,
J. Cansfield,
Kwai-Ming J. Cheung,
I. Collins,
N. Davies,
M. Drysdale,
B. Dymock,
S. Eccles,
H. Finch,
A. Fink,
A. Hayes,
...
R. Howes,
R. Hubbard,
K. James,
A. Jordan,
A. Lockie,
V. Martins,
A. Massey,
Thomas P Matthews,
E. McDonald,
Christopher J. Northfield,
L. Pearl,
C. Prodromou,
S. Ray,
F. Raynaud,
S. Roughley,
S. Sharp,
A. Surgenor,
D. Walmsley,
P. Webb,
Mike Wood,
P. Workman,
L. Wright
|
8 |
2007 |
8
π
|
|
π
|
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
12 auth.
C. Ryan,
Matthew R. Smith,
L. Fong,
J. Rosenberg,
P. Kantoff,
F. Raynaud,
...
V. Martins,
Gloria Lee,
T. Kheoh,
Jennifer Kim,
A. Molina,
E. Small
|
8 |
2010 |
8
π
|
|
π¦
|
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
25 auth.
F. Raynaud,
S. Eccles,
P. Clarke,
A. Hayes,
B. Nutley,
Sonia Alix,
Alan T. Henley,
Francesca Di-Stefano,
Zahida Ahmad,
Sandrine Guillard,
Lynn Bjerke,
L. Kelland,
M. Valenti,
Lisa Patterson,
S. Gowan,
...
A. K. de Haven Brandon,
M. Hayakawa,
Hiroyuki Kaizawa,
Tomonubu Koizumi,
T. Ohishi,
Sonal Patel,
N. Saghir,
P. Parker,
M. Waterfield,
P. Workman
|
8 |
2007 |
8
π¦
|
|
π
|
Hormonal impact of the 17Ξ±-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
11 auth.
A. OβDonnell,
I. Judson,
M. Dowsett,
F. Raynaud,
D. Dearnaley,
M. Mason,
...
S. Harland,
A. Robbins,
G. Halbert,
B. Nutley,
M. Jarman
|
8 |
2004 |
8
π
|
|
π
|
First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial
9 auth.
A. Webb,
D. Cunningham,
F. Cotter,
P. Ross,
J. Walters,
I. Judson,
...
F. Raynaud,
P. Clarke,
Z. Dziewanowska
|
8 |
1997 |
8
π
|
